This HTML5 document contains 89 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n20http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/pdb/
n26http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/kegg-compound/
n32http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/pubchem-substance/
n18http://bio2rdf.org/drugbank:
n28http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/national-drug-code-directory/
n13http://www.rxlist.com/cgi/generic/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n31http://linked.opendata.cz/ontology/mesh/
n33http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n3http://linked.opendata.cz/ontology/drugbank/
n30http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/chemspider/
n16http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n29http://linked.opendata.cz/resource/drugbank/drug/DB01093/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01093
rdf:type
n3:Drug
n3:description
A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during cryopreservation. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation. [PubChem]
n3:dosage
n11:271B64F8-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:indication
For the symptomatic relief of patients with interstitial cystitis.
owl:sameAs
n9:DB01093 n18:DB01093
dcterms:title
Dimethyl sulfoxide
adms:identifier
n20:Dimethyl_sulfoxide n21:46505009 n22:PA449342 n23:679 n24:67457-177-50 n25:DMS n26:C11143 n27:D01043 n28:DB01093 n29:28262 n30:659
n3:mechanismOfAction
The mechanism of dimethyl sulfoxide's actions is not well understood. Dimethyl sulfoxide has demonstrated antioxidant activity in certain biological settings. For example, the cardiovascular protective effect of dimethyl sulfoxide in copper-deficient rats is thought to occur by an antioxidant mechanism. It is also thought that dimethyl sulfoxide's possible anti-inflammatory activity is due to antioxidant action.
n3:packager
n5:271B64EC-363D-11E5-9242-09173F13E4C5 n5:271B64ED-363D-11E5-9242-09173F13E4C5 n5:271B64F0-363D-11E5-9242-09173F13E4C5 n5:271B64EE-363D-11E5-9242-09173F13E4C5 n5:271B64EF-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Dimethyl sulfoxide and dimethyl sulfone are excreted in the urine and feces.
n3:synonym
Dimetil sulfoxido Sulfinylbis(methane) Dimethyli sulfoxidum DMSO Dimethyl sulfoxide Methylsulfinylmethane S(O)Me2 Dimethylsulfoxid (CH3)2SO Dimethyl sulphoxide Dimethylsulfoxyde Dimethyl sulfur oxide
n3:toxicity
The oral LD<sub>50</sub> of dimethyl sulfoxide in the dog is greater than 10 gm/kg. It is improbable that this dosage level could be obtained with intravesical instillation of dimethyl sulfoxide in the patient.
n6:hasAHFSCode
n7:40-36-00 n7:92-00-00
n3:mixture
n15:271B64EB-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Zhi Guo, Indra Prakash, "Synthesis and purification of 3,3-dimethylbutyraldehyde via oxidation of 1-chloro-3,3-dimethylbutane with dimethyl sulfoxide." U.S. Patent US5905175, issued October, 1990.
n31:hasConcept
n32:M0006456
foaf:page
n13:dmso.htm n16:dimethyl-sulfoxide.html n33:dim_0098.shtml
n3:IUPAC-Name
n4:271B64FD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6503-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6502-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B64FF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6500-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6501-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B64FB-363D-11E5-9242-09173F13E4C5 n4:271B6512-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B64F9-363D-11E5-9242-09173F13E4C5 n4:271B64FC-363D-11E5-9242-09173F13E4C5 n4:271B6515-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B64FA-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n10:G04BX13 n10:M02AX03
n3:H-Bond-Acceptor-Count
n4:271B6509-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B650A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6504-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6505-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6507-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6506-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6508-363D-11E5-9242-09173F13E4C5
n3:absorption
Readily and rapidly absorbed following administration by all routes and distributed throughout the body.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
67-68-5
n3:category
n3:containedIn
n17:271B64F1-363D-11E5-9242-09173F13E4C5 n17:271B64F2-363D-11E5-9242-09173F13E4C5 n17:271B64F5-363D-11E5-9242-09173F13E4C5 n17:271B64F6-363D-11E5-9242-09173F13E4C5 n17:271B64F3-363D-11E5-9242-09173F13E4C5 n17:271B64F4-363D-11E5-9242-09173F13E4C5 n17:271B64F7-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B650E-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B6514-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6510-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6511-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B6513-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B650D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B650C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B650F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B64FE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B650B-363D-11E5-9242-09173F13E4C5